Richtlijn CVRM feb2013 - KNMP

Peto 2008 Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al. Analyses of cancer data
from three ezetimibe trials. N Engl J Med. 2008 25;359(13):1357-66.
Peuter de 2011
De Peuter OR, Kok WE, Buller HR, Kamphuisen PW. De invloed van niet-selectieve versus selectieve
bètablokkers op stollingsgerelateerde events bij patiënten met hartfalen. Hartbulletin 2011; 42: 132-
135.
Pfingsterer 2006 Pfingsterer M, Brunner-LA Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late
clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. JACC
2006; 12: 2584-91.
PHARMO 2006 PHARMO instituut (anonymous). Therapieontrouw statines gevaarlijk. Pharm Weekblad 2006; 50:1584.
Philips 2007
Pink 2011
Philips CO, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensinconverting
enzyme inhibitors for left ventricular dysfunction. Arch Intern Med 2007; 167: 1930-1936.
Pink J, lane S, Pirmohamed M. Dabigatran etexilate versus warfarin in management of nonvalvular
atrial fibrillation in UK contaxt: quantitative benefit-harm en economic analyses. BMJ
2011: 343: d6333.
Poelmann 2012 Poelmann T, Blanker M. Dipyridamol effectief na TIA of herseninfarct H&W 2012; 55 (2): 93.
Preiss 2011 Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes
with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305: 2556- 2564.
Psaty 2003
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes
associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
JAMA 2003; 289: 2534-2544.
Quinlan 2011 Quinlan DJ, Eikelboom JW, Goodman SG, Welsh RC, Fitchett DH, Theroux P, et al.
Implications of variability in definition and reporting of major bleeding in randomized trials of
P2Y12 inhibitors for acute coronary syndromes. Eur Heart J 2011; 32 (18): 2256-65.
oral
Räber 2012 Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newergeneration
everolimus-eluting stent compared with early-generation drug-eluding stents: a
prospective cohort study. Circulation. 2012; 125: 1110-21.
Ray 2005 Ray KK, Cannon CP. The potential relevance of multiple lipid-independent (pleiotropic)
effects of statins in the management of actue coronary syndromes. JACC 2005; 46 (8): 1425- 1433.
Ray 2010 Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema W, Ford I, et al. Statins and All-cause
mortality in high-risk primary prevention. A meta analysis of 11 randomized controlled trials
involving 65229 participants. Arch Intern Med 2010; 170 (12): 1024-1031.
Reriani 2011 Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO e.a. Effects of statins on
coronary and peripheral endothelial function in humans: a systematic review and meta
analysis of randomized controlled trials. European Journal of Cardiov Prev & Rehabilitation 2011;
18 (5): 704-716.
Rezaie 2002 Rezaie-Majid A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, et al. Simvastatin
reduces ther expression of adhesion molecules in circulating monocytes from
hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003; 23: 397-403.
Ribeiro 2011 Ribeiro RA, Ziegelmann PK, Duncan BB, Stella SF, da Costa Vieira JL, Restelatto LM, et al.
Impact of statin dose on major cardiovascular events: A mixed treatment comparison metaanalysis
involving more than 175,000 patients. Int J Cardiol 2011; epub ahead of print. PMID:
22192281.
Ridker 2001 Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Lies JS, et al. Measurement of C-reactive
protein for the targeting of statin therapy in the primary prevention of acute coronary
events. N Engl J Med 2001; 344 (26): 1959-1965.
Ridker 2005 Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin
therapy. N Eng J Med 2005; 352: 20-8.
CONCEPT
96